{"entity":{"id":"nct05720117","kind":"trial","name":"A Study of PYX-201 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of Micvotabart pelidotin run by Pyxis Oncology, Inc, now recruiting.","summary":"A Study of PYX-201 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05720117 by Pyxis Oncology, Inc, with 330 participants planned, started 2023-03-14, primary completion expected 2027-04-25. Conditions recorded: Solid Tumor, Advanced Solid Tumor. Interventions recorded: PYX-201.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05720117","url":"https://clinicaltrials.gov/study/NCT05720117"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["micvotabart-pelidotin"],"companies":["pyxis-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05720117","phase":"1","setting":"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors","sponsor":"Pyxis Oncology, Inc","enrolled":330,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05720117/","neighbours":{"drug":[{"id":"micvotabart-pelidotin","kind":"drug","name":"Micvotabart pelidotin","route":"/drugs/micvotabart-pelidotin/"}],"company":[{"id":"pyxis-oncology","kind":"company","name":"Pyxis Oncology","route":"/companies/pyxis-oncology/"}]}}